226 related articles for article (PubMed ID: 21385795)
1. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.
Witherby S; Johnson J; Demers L; Mount S; Littenberg B; Maclean CD; Wood M; Muss H
Oncologist; 2011; 16(4):424-31. PubMed ID: 21385795
[TBL] [Abstract][Full Text] [Related]
2. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
3. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
Davis SR; Robinson PJ; Jane F; White S; White M; Bell RJ
J Clin Endocrinol Metab; 2018 Nov; 103(11):4146-4154. PubMed ID: 30239842
[TBL] [Abstract][Full Text] [Related]
4. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
Donders G; Neven P; Moegele M; Lintermans A; Bellen G; Prasauskas V; Grob P; Ortmann O; Buchholz S
Breast Cancer Res Treat; 2014 Jun; 145(2):371-9. PubMed ID: 24718774
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
Hirschberg AL; Sánchez-Rovira P; Presa-Lorite J; Campos-Delgado M; Gil-Gil M; Lidbrink E; Suárez-Almarza J; Nieto-Magro C
Menopause; 2020 May; 27(5):526-534. PubMed ID: 32049923
[TBL] [Abstract][Full Text] [Related]
6. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
Moegele M; Buchholz S; Seitz S; Ortmann O
Arch Gynecol Obstet; 2012 May; 285(5):1397-402. PubMed ID: 22212649
[TBL] [Abstract][Full Text] [Related]
7. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study.
Mension E; Alonso I; Cebrecos I; Castrejon N; Tortajada M; Matas I; Gómez S; Ribera L; Anglès-Acedo S; Castelo-Branco C
Climacteric; 2022 Oct; 25(5):476-482. PubMed ID: 35343852
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
9. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
Buchholz S; Mögele M; Lintermans A; Bellen G; Prasauskas V; Ortmann O; Grob P; Neven P; Donders G
Climacteric; 2015 Apr; 18(2):252-9. PubMed ID: 25427450
[TBL] [Abstract][Full Text] [Related]
10. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
11. Vaginal Testosterone for Management of Aromatase Inhibitor-Related Sexual Dysfunction: An Integrative Review.
Lemke EA; Madsen LT; Dains JE
Oncol Nurs Forum; 2017 May; 44(3):296-301. PubMed ID: 28635978
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Streff A; Chu-Pilli M; Stopeck A; Chalasani P
Support Care Cancer; 2021 Jan; 29(1):187-191. PubMed ID: 32328775
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.
Sánchez-Rovira P; Hirschberg AL; Gil-Gil M; Bermejo-De Las Heras B; Nieto-Magro C
Oncologist; 2020 Dec; 25(12):e1846-1854. PubMed ID: 32459035
[TBL] [Abstract][Full Text] [Related]
14. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).
Barton DL; Shuster LT; Dockter T; Atherton PJ; Thielen J; Birrell SN; Sood R; Griffin P; Terstriep SA; Mattar B; Lafky JM; Loprinzi CL
Support Care Cancer; 2018 Apr; 26(4):1335-1343. PubMed ID: 29164377
[TBL] [Abstract][Full Text] [Related]
15. Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
Sulaica E; Han T; Wang W; Bhat R; Trivedi MV; Niravath P
Breast Cancer Res Treat; 2016 Jun; 157(2):203-210. PubMed ID: 27178335
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
Kallak TK; Baumgart J; Göransson E; Nilsson K; Poromaa IS; Stavreus-Evers A
Menopause; 2014 Apr; 21(4):383-90. PubMed ID: 24080848
[TBL] [Abstract][Full Text] [Related]
17. Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
Mariani L; Gadducci A; Vizza E; Tomao S; Vici P
Gynecol Endocrinol; 2013 Jan; 29(1):25-9. PubMed ID: 22994445
[TBL] [Abstract][Full Text] [Related]
18. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
[TBL] [Abstract][Full Text] [Related]
19. [Vaginal oestrogen therapy in women with hormone-sensitive breast cancer].
Bak AM; Laursen BE; Rungby J; Brock B
Ugeskr Laeger; 2011 Feb; 173(9):648-51. PubMed ID: 21362392
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.
Fernandes T; Costa-Paiva LH; Pedro AO; Baccaro LF; Pinto-Neto AM
Menopause; 2016 Jul; 23(7):792-8. PubMed ID: 27116462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
